Fidaxomicin: A minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 8, 2013, Pages 767-776

  Soriano, Melinda M ^a   Liao, Siyun ^a   Danziger, Larry H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Clostridium difficile; Dificid; fidaxomicin

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DRUG METABOLITE; ERYTHROMYCIN; FIDAXOMICIN; MACROCYCLIC COMPOUND; MACROLIDE; METRONIDAZOLE; VANCOMYCIN;

ABDOMINAL PAIN; ANGINA PECTORIS; ANTIBACTERIAL ACTIVITY; ASYMPTOMATIC INFECTION; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM PERFRINGENS; CONJUNCTIVITIS; CONSTIPATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; EOSINOPHILIA; HEADACHE; HUMAN; HYPOKALEMIA; IMMUNOCOMPROMISED PATIENT; KIDNEY COLIC; LEUKOPENIA; LIMB PAIN; MALIGNANT NEOPLASTIC DISEASE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PATHOGENESIS; PHARMACODYNAMICS; PHARYNGITIS; PNEUMONIA; PRACTICE GUIDELINE; RECURRENCE RISK; RECURRENT INFECTION; REVIEW; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEAKNESS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COSTS AND COST ANALYSIS; HUMANS;

EID: 84887590367     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.814767     Document Type: Review

References (70)

1. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-Associated diarrhea: A review. Arch. Intern. Med. 161(4), 525-533 (2001
2. Goorhuis A, Bakker D, Corver J et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin. Infect. Dis. 47(9), 1162-1170 (2008
3. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353(23), 2433-2441 (2005
4. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin. Infect. Dis. 55 (Suppl. 2), S65-S70 (2012
5. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-Associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173(9), 1037-1042 (2005
6. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-Associated Clostridium difficile Infection and of healthcare-Associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect. Control. Hosp. Epidemiol. 32(4), 387-390 (2011
7. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch. Surg. 142(7), 624-631 (2007
8. Pawar D, Tsay R, Nelson DS et al. Burden of Clostridium difficile infection in long-Term care facilities in Monroe County, New York. Infect. Control Hosp. Epidemiol. 33(11), 1107-1112 (2012
9. Weir E, Flegel K. Protecting against Clostridium difficile illness. Cmaj 172(9), 1178 (2005
10. Cleary RK. Clostridium difficile-Associated diarrhea and colitis: Clinical manifestations, diagnosis, and treatment. Dis. Colon Rectum 41(11), 1435-1449 (1998
11. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin. Infect. Dis. 53(1), 42-48 (2011
12. Chen FC, Woods R. Pseudomembranous panenteritis and sePTicaemia in a patient with ulcerative colitis. Aust. N. Z. J. Surg. 66(8), 565-567 (1996
13. Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-Associated diarrhea: A cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41(9), 1254-1260 (2005
14. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-Associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353(23), 2442-2449 (2005
15. Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: An underappreciated and increasing cause of death and complications. Ann. Surg. 235(3), 363-372 (2002
16. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficileassociated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control. Hosp. Epidemiol. 26(3), 273-280 (2005
17. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin. Infect. Dis. 40(2), 265-272 (2005
18. Hensgens MP, Goorhuis A, Notermans DW, van Benthem BH, Kuijper EJ. Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands. Euro. Surveill. 14(45), (2009
19. Wilcox MH, Shetty N, Fawley WN et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin. Infect. Dis. 55(8), 1056-1063 (2012
20. ODonoghue C, Kyne L. Update on Clostridium difficile infection. Curr. Opin. Gastroenterol. 27(1), 38-47 (2011
21. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control. Hosp. Epidemiol. 31(5), 431-455 (2010
22. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 15(12), 1067-1079 (2009
23. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 97(7), 1769-1775 (2002
24. Barbut F, Richard A, Hamadi K et al. Epidemiology of recurrences or reinfections of Clostridium difficile-Associated diarrhea. J. Clin. Microbiol. 38(6), 2386-2388 (2000
25. Fekety R, McFarland LV, Surawicz CM et al. Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin. Infect. Dis. 24(3), 324-333 (1997
26. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: A systematic review. J. Hosp. Infect. 74(4), 309-318 (2010
27. Dificid® package insert. OPTimer Pharmaceuticals, Inc., San Diego, CA, USA (2013
28. Crook DW, Walker AS, Kean Y et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: Metaanalysis of pivotal randomized controlled trials. Clin. Infect. Dis. 55(Suppl. 2), S93-103 (2012
29. Venugopal AA, Johnson S. Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin. Infect. Dis. 54(4), 568-574 (2012
30. Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob. Agents Chemother. 48(12), 4898-4902 (2004
31. Anti-Infective Drugs Advisory Committee Briefing Document OPTimer Pharmaceuticals I. Dificid (fidaxomicin tablets) for the treatment of Clostridium difficile infection (CDI), also known as Clostridium difficileassociated diarrhea (CDAD), and for reducing the risk of recurrence when used for treatment of initial CDI. (Ed. (Eds) (2011
32. Sergio S, Pirali G, White R, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action. J. Antibiot. (Tokyo), 28(7), 543-549 (1975
33. Osburne MS, Sonenshein AL. Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis. J. Virol. 33(3), 945-953 (1980
34. Artsimovitch I, Seddon J, Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin. Infect. Dis. 55(Suppl. 2), S127-S131 (2012
35. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. 48(11), 4430-4434 (2004
36. Goldstein EJ, Citron DM, Sears P et al. Comparative suscePTibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two Phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob. Agents Chemother. 55(11), 5194-5199 (2011
37. Babakhani F, Gomez A, Robert N, Sears P. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob. Agents Chemother. 55(9), 4427-4429 (2011
38. Babakhani F, Bouillaut L, Sears P et al. Fidaxomicin inhibits toxin production in Clostridium difficile. J. Antimicrob. Chemother. 68(3), 515-522 (2013
39. Babakhani F, Bouillaut L, Gomez A et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin. Infect. Dis. 55(Suppl. 2), S162-S169 (2012
40. Louie TJ, Cannon K, Byrne B et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin. Infect. Dis. 55(Suppl. 2), S132-S142 (2012
41. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 53(1), 261-263 (2009
42. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin. Infect. Dis. 25(3), 729-732 (1997
43. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycinresistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin. Infect. Dis. 55(Suppl. 2), S121-S126 (2012
44. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a Phase II trial with patients with Clostridium difficile infection. Antimicrob. Agents Chemother. 53(1), 223-228 (2009
45. Al-Nassir WN, Sethi AK, Li Y et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-Associated disease. Antimicrob. Agents Chemother. 52(7), 2403-2406 (2008
46. Shue YK, Sears PS, Shangle S et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob. Agents Chemother. 52(4), 1391-1395 (2008
47. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364(5), 422-431 (2011
48. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12(4), 281-289 (2012
49. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: Fidaxomicin versus vancomycin. Clin. Infect. Dis. 55(Suppl. 2), S154-S161 (2012
50. Mullane KM, Miller MA, Weiss K et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis. 53(5), 440-447 (2011
51. Cornely OA, Miller M, Fantin B, Mullane K, Kean Y, Gorbach S. Clostridium difficile-Associated Diarrhea in Cancer Patients Treated with Fidaxomicin or Vancomycin. Presented at: Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, 2012
52. Mullane K, Golan Y, Crook D, Cornely O, Miller M, Louie T, Gorbach S. Renal Impairment and Responses to Fidaxomicin versus Vancomycin in Patients with Clostridium difficile Infection. Presented at: Society of Hospital Medicine Annual Meeting. San Diego, CA, 2012
53. Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-Associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. Cmaj 171(5), 466-472 (2004
54. Miller M, Gravel D, Mulvey M et al. Health care-Associated Clostridium difficile infection in Canada: Patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin. Infect. Dis. 50(2), 194-201 (2010
55. Bloomfield MG, Sherwin JC, Gkrania-Klotsas E. Risk factors for mortality in Clostridium difficile infection in the general hospital population: A systematic review. J. Hosp. Infect. 82(1), 1-12 (2012
56. Louie TJ, Miller MA, Crook DW et al. Effect of age on treatment outcomes in Clostridium difficile infection. J. Am. Geriatr. Soc. 61(2), 222-230 (2013
57. Johnson S, Gerding DN. Fidaxomicin chaser regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin. Infect. Dis. 56(2), 309-310 (2013
58. Weiss K, Allgren RL, Sellers S. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections. Clin. Infect. Dis. 55(Suppl. 2), S110-S115 (2012
59. Sclar DA, Robison LM, Oganov AM et al. Fidaxomicin for Clostridium difficileassociated diarrhoea: Epidemiological method for estimation of warranted price. Clin. Drug. Investig. 32(8), e17-e24 (2012
60. Kuntz JL, Johnson ES, Raebel MA et al. Epidemiology and healthcare costs of incident Clostridium difficile infections identified in the outpatient healthcare setting. Infect. Control Hosp. Epidemiol. 33(10), 1031-1038 (2012
61. McGlone SM, Bailey RR, Zimmer SM et al. The economic burden of Clostridium difficile. Clin. Microbiol. Infect. 18(3), 282-289 (2012
62. McFarland LV, Surawicz CM, Rubin M et al. Recurrent Clostridium difficile disease: Epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 20(1), 43-50 (1999
63. OBrien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-Associated disease in Massachusetts hospitals: Clinical and economic consequences. Infect. Control Hosp. Epidemiol. 28(11), 1219-1227 (2007
64. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34(3), 346-353 (2002
65. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin. Infect. Dis. 55(Suppl 2), S88-S92 (2012
66. Greig J. Fidaxomicin in the treatment of Clostridium difficile-Associated diarrhoea. Clin. Drug Investig. 33(1), 93-94 (2013
67. Crawford T, Huesgen E, Danziger L. Fidaxomicin: A novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am. J. Health. Syst. Pharm. 69(11), 933-943 (2012
68. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-Associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45(3), 302-307 (2007
69. Le F, Arora V, Shah DN et al. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: Implications for antibiotic stewardship programs. Pharmacotherapy 32(2), 129-134 (2012
70. Louie T, Gerson M, Grimard D et al. Results of a Phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficileassociated diarrhea (CDAD). Presented at: Interscience Conference of Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 SePTember 2007 (Abstract K-425a